Biohaven Ltd. (NYSE:BHVN) Shares Purchased by RWA Wealth Partners LLC

RWA Wealth Partners LLC grew its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 81.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,800 shares of the company’s stock after purchasing an additional 5,300 shares during the quarter. RWA Wealth Partners LLC’s holdings in Biohaven were worth $441,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of BHVN. Point72 Asset Management L.P. raised its stake in Biohaven by 745.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock worth $74,969,000 after acquiring an additional 1,322,922 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Biohaven by 144.5% during the fourth quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company’s stock worth $73,922,000 after purchasing an additional 1,169,721 shares in the last quarter. Norges Bank purchased a new stake in shares of Biohaven in the 4th quarter valued at about $33,711,000. Vanguard Group Inc. boosted its position in shares of Biohaven by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company’s stock valued at $314,267,000 after purchasing an additional 628,211 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Biohaven by 563.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company’s stock worth $25,416,000 after buying an additional 431,954 shares during the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analyst Ratings Changes

BHVN has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the company a “buy” rating in a research note on Thursday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. HC Wainwright reissued a “buy” rating and set a $54.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. lowered their target price on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Fourteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $62.77.

Biohaven Trading Down 6.0 %

Shares of BHVN opened at $22.60 on Wednesday. The firm’s 50-day moving average is $34.55 and its two-hundred day moving average is $41.21. Biohaven Ltd. has a twelve month low of $21.47 and a twelve month high of $55.72. The firm has a market capitalization of $2.31 billion, a P/E ratio of -2.42 and a beta of 1.27.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Analysts predict that Biohaven Ltd. will post -8.9 EPS for the current year.

Insider Activity

In related news, Director John W. Childs acquired 32,700 shares of Biohaven stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the transaction, the director now directly owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 16.00% of the company’s stock.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.